Login to Your Account

Israeli Biotech Sector Maturing, Seeking U.S. Investors

By Vicki Brower

Friday, December 10, 2010
NEW YORK – In spite of having the world's highest number of life science patents per capita, a highly developed academic research infrastructure, and entrepreneurial know-how, Israel still has trouble commercializing its discoveries due to a number of factors, mostly financing. But the Israeli biotech industry is finally coming of age, according to 14 company presentations at this week's Tel Aviv Stock Exchange (TASE)-NASDAQ Biomed Conference held at NASDAQ's New York headquarters.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription